The Forever Chemicals Prohibition Act prohibits the sale or offer for sale in Nova Scotia of products that contain intentionally added perfluoroalkyl and polyfluoroalkyl substances (PFAS) beginning January 1, 2028. The ban excludes medical devices that have federal approval and a narrow "essential product" carve‑out where no reasonable non‑PFAS alternative exists.
The bill is tightly focused: it targets intentionally added PFAS in products placed on the market in the province rather than incidental contamination, and it creates an offence for contravention without specifying penalties or an administrative enforcement framework. For businesses, suppliers and regulators, the act raises immediate questions about supply‑chain screening, proof of absence, and how exemptions will be determined and implemented.
At a Glance
What It Does
The Act makes it an offence to sell or offer for sale in Nova Scotia any product that contains intentionally added PFAS after January 1, 2028, while exempting federal Health Canada‑approved medical devices and products the Act classifies as "essential." It defines the key terms "intentionally added PFAS" and "essential product," but it does not prescribe an enforcement agency, inspection powers, or penalties.
Who It Affects
Retailers, importers, and manufacturers who supply consumer and industrial products into Nova Scotia will need to determine whether their goods contain intentionally added PFAS. Testing labs, compliance teams and upstream suppliers will face increased demand for documentation and disclosure; municipal water managers and public‑health officials are indirect beneficiaries of reduced sources of PFAS entering waste streams.
Why It Matters
This is a province‑level attempt to eliminate a broad class of persistent chemicals from products, shifting the regulatory trigger from concentration‑based limits to the presence of intentionally added PFAS. The statute's narrow definitions and limited procedural detail mean much of its real‑world effect will turn on implementation choices—how firms demonstrate compliance and how authorities interpret the "essential product" test.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act sets a single, bright‑line obligation: starting January 1, 2028, sellers in Nova Scotia may not sell or offer for sale products that include PFAS deliberately added to achieve a function in the finished good or a component. The ban applies to sales within the province regardless of where the product was manufactured, and it targets the act of placing an intentionally PFAS‑containing product on the Nova Scotian market rather than ambient environmental contamination.
Two narrow exceptions limit the ban. First, the Act excludes medical devices that have received approval from Health Canada; those federally authorized products may continue to be sold.
Second, the statute allows exceptions for "essential products," defined as those necessary for health, safety or societal functioning and for which a non‑PFAS alternative is not reasonably available. The text does not create a process for declaring a product essential or assign responsibility for making that determination.The Act criminalizes non‑compliance by making contravention an offence, but it does not set out fines, administrative penalties, inspection powers, recall authority, or a compliance regime.
That omission means enforcement will rely on prosecutorial discretion or future regulations. For businesses, the immediate compliance tasks will be mapping product formulations, collecting manufacturer declarations, and deciding whether an item meets the "intentionally added" threshold—an evidentiary standard that will hinge on supply‑chain records and possibly chemical testing.Because the statute distinguishes intentionally added PFAS from trace contamination, manufacturers may avoid the ban by showing PFAS are incidental impurities rather than functional ingredients.
That creates an evidentiary boundary that testing alone may not resolve; records about manufacturing intent, formulation specifications and supplier declarations will likely be decisive. The interplay with federal approvals for medical devices and the undefined "essential product" route are the main implementation levers that will determine how sweeping the ban actually is.
The Five Things You Need to Know
The ban takes effect January 1, 2028 and applies to any sale or offer for sale in Nova Scotia of products containing PFAS that were intentionally added during manufacture.
The statute exempts medical devices that have been approved by Health Canada; the provincial law defers to federal authorizations in this category.
A product qualifies as an "essential product" only if it is necessary for health, safety or societal functioning and there is no reasonably available alternative that does not contain PFAS—however, the bill does not specify who decides or how that test is administered.
The Act criminalizes violations by creating an offence for contravening the prohibition, but it contains no prescribed penalties, fines, administrative sanctions, recall powers, or designated enforcement body.
The prohibition targets "intentionally added PFAS," excluding PFAS present only as contaminants or by‑products, which shifts compliance emphasis from concentration thresholds to documentation of manufacturing intent.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title — how to cite the law
This single‑line provision gives the statute its operative name, the Forever Chemicals Prohibition Act. That matters for legal drafting and regulatory cross‑references: subsequent regulations, guidance or enforcement notices will cite this Act as the authority for product‑level PFAS restrictions.
Key definitions that set the legal boundaries
Section 2 defines three crucial terms: "essential product," "intentionally added PFAS," and "PFAS." The "intentionally added" definition creates a threshold that imports the manufacturer's intent and function into legal analysis—compliance will therefore depend on production records and supplier statements as much as on chemical assays. The "essential product" definition creates a carve‑out but lacks any procedural mechanism, evidentiary standard beyond the "not reasonably available" phrase, or timeline for determinations, leaving significant discretion to whoever enforces the law.
Primary prohibition and narrow exceptions
Section 3 implements the ban: after the specified date, no person may sell or offer for sale in the province any product with intentionally added PFAS, except for two categories—Health Canada‑approved medical devices and products qualifying as essential. The use of "sell or offer for sale" captures retailers and distributors and can apply to online offerings targeted to Nova Scotia. The reliance on federal medical device approvals requires cross‑jurisdictional coordination; the essential product exception introduces a facts‑intensive inquiry that could become the focal point of compliance disputes.
Offence provision without penalty or enforcement detail
Section 4 states that contravening the Act is an offence but supplies no further enforcement architecture—no specified fines, no administrative remedies, no designated inspectorate and no process for recalls or corrective orders. That omission means the practical enforceability of the ban will depend on subsequent regulation, prosecution practices, or other statutory tools. It also creates legal uncertainty for businesses deciding whether to withdraw products or seek judicial clarification of the Act's scope.
This bill is one of many.
Codify tracks hundreds of bills on this topic across all five countries.
Explore this topic in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Residents of Nova Scotia concerned about long‑lasting chemical exposures — the ban reduces the flow of products that deliberately rely on PFAS into provincial waste streams and households, lowering potential sources of local contamination over time.
- Municipal water and wastewater managers — fewer PFAS‑bearing products entering municipal systems could reduce treatment burdens and lower monitoring and remediation costs in the medium term.
- Producers of PFAS‑free alternatives — manufacturers that already use alternative chemistries or materials gain market access as PFAS‑containing competitors are removed from the provincial market.
- Public‑health and environmental NGOs — the Act provides a legal tool to pressure supply chains and public purchasers to prefer PFAS‑free products, aligning procurement and advocacy strategies with provincial law.
Who Bears the Cost
- Retailers and importers selling consumer and industrial products into Nova Scotia — they must audit inventories, demand supplier disclosures, and potentially withdraw or relabel products, imposing compliance and commercial costs.
- Manufacturers whose formulations include functional PFAS — companies will face reformulation costs, certification and testing expenses, and potential loss of market access in the province absent acceptable alternatives.
- Provincial regulators and enforcement bodies — because the Act lacks an enforcement framework, the Province will either need to create inspection and enforcement capacity or rely on existing agencies to absorb new responsibilities, requiring budget and regulatory design work.
- Testing laboratories and compliance consultants — while these actors may see increased demand, small firms face operational scaling challenges and the burden of developing PFAS‑specific assays and chain‑of‑custody procedures.
- Small businesses and specialty suppliers — niche producers may find it expensive to prove their products fall outside the ban (for example, showing PFAS are incidental and not intentionally added), raising transaction costs that disproportionately affect smaller firms.
Key Issues
The Core Tension
The central dilemma is between the public‑health goal of rapidly removing deliberately added PFAS from consumer and industrial products and the legal and administrative need for clear, enforceable rules: the bill pursues a broad public‑health objective but provides little guidance on how to decide exemptions, prove compliance, or enforce the rule without creating economic disruption or legal uncertainty.
The Act creates a strong normative stance against intentionally added PFAS but leaves major implementation questions unresolved. First, the legal line between "intentionally added" and incidental contamination will require clear standards and evidentiary rules; absent that, compliance will be document‑driven and costly to litigate.
Second, the "essential product" exception is substantive but procedurally vacuous: the statute does not establish who evaluates claims of essentiality, what proof is required, whether decisions are reviewable, or how long an exemption lasts. Those omissions invite inconsistent treatment across cases and potential business uncertainty.
A second set of trade‑offs concerns enforcement design. By creating an offence without specifying penalties or administrative remedies, the Act places a choice before the Province: pursue criminal prosecutions (slow and resource‑intensive) or develop accompanying regulations that create administrative penalties, inspection powers and recall mechanisms.
The absence of an express enforcement authority also raises the prospect that the ban will have uneven deterrent effect until a regulatory framework or prosecutorial policy fills the gap. Finally, operationalizing the ban will require cross‑jurisdictional coordination with federal regulators (Health Canada) and may strain supply chains that operate nationally or internationally, producing tension between provincial public‑health objectives and practical market realities.
There's more to this law than the bill.
Codify Laws traces every connection across the legislative lifecycle.